Calcifediol extended release - OPKO Renal

Drug Profile

Calcifediol extended release - OPKO Renal

Alternative Names: CTAP-101; CTAP101 Capsules; Modified-release calcifediol - OPKO; Rayaldee; Rayaldy

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytochroma
  • Developer OPKO Renal
  • Class Calcium regulators; Osteoporosis therapies; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Secondary hyperparathyroidism
  • No development reported Bone disorders

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Bone-disorders(Adjunctive treatment, Prevention) in USA (PO, Capsule)
  • 12 Oct 2017 Extended release calcifediol licensed to Japan Tobacco for the treatment of Secondary hyperparathyroidism in Japan
  • 01 Mar 2017 OPKO Renal and Vifor Fresenius Medical Care Renal Pharma plan a phase II trial for Secondary hyperparathyroidism in 2H 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top